Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 7728-7736

  Chen, Yu ^a   Guo, Zeng Qing ^a,b   Shi, Chun Mei ^a,b   Zhou, Zhi Feng ^a,b   Ye, Yun Bin ^a,b   Chen, Qiang ^a,b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Key Laboratory of Translational Cancer Medicine   (China)

Author keywords

Adjuvant chemotherapy; Cytokine induced killer cells; D2 gastrectomy; Gastric cancer; Immunotherapy

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CREATININE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; GASTRECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER;

EID: 84937010673     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. [1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. [2] Chen W, Zheng R, Zeng H, Zhang S and He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015; 27: 2-12.
3. [3] Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490.
4. [4] Gallo A and Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12: 3237-3242.
5. [5] Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F and Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321.
6. [6] Park JM and Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res 2008; 2: 137-144.
7. [7] Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO). Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014; 40: 584-91
8. [8] Ilson DH. Adjuvant treatment for gastric cancer: too much is not enough. Lancet Oncol 2014; 15: 788-789.
9. [9] Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011; 137: 305-310.
10. [10] Mellman I, Coukos G and Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
11. [11] Dougan M and Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
12. [12] Jakel CE and Schmidt-Wolf IG. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther 2014; 14: 905-916.
13. [13] Lu PH and Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696.
14. [14] Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
15. [15] Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J and Introna M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009; 37: 616-628.
16. [16] Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M and Cignetti A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008; 20: 841-848.
17. [17] Mehta BA, Schmidt-Wolf IG, Weissman IL and Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995; 86: 3493-3499.
18. [18] Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-1679.
19. [19] Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J and Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011; 118: 3301-3310.
20. [20] Verneris MR, Ito M, Baker J, Arshi A, Negrin RS and Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001; 7: 532-542.
21. [21] Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L and Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-6186.
22. [22] Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96: 6879-6884.
23. [23] Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY and Ye YB. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS One 2013; 8: e69044.
24. [24] Zhao H, Fan Y, Li H, Yu J, Liu L, Cao S, Ren B, Yan F and Ren X. Immunotherapy with Cytokine-Induced Killer Cells as an Adjuvant Treatment for Advanced Gastric Carcinoma: A Retro-spective Study of 165 Patients. Cancer Biother Radiopharm 2013; 28: 303-309.
25. [25] Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J and Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012; 61: 2251-2259.
26. [26] Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF and Zhang XG. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16: 6155-6162.
27. [27] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
28. [28] Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
29. [29] Gallo A and Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12: 3237-3242.
30. [30] Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. Semin Radiat Oncol 2002; 12: 150-161.
31. [31] Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo DL, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M and Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012; 12: 673-684.
32. [32] Liu H, Song J, Yang Z and Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 2013; 6: 953-956.
33. [33] Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J and Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012; 61: 2251-2259.